Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients
- 1 April 2006
- journal article
- research article
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 22 (4) , 321-329
Abstract
Using a multicenter, cross-sectional, observation study, the long-term safety, metabolic profile, and viral efficacy of nevirapine (NVP)-based approaches in HIV-1-infected patients treated for at least 2 years were assessed. For 4 months, all consecutive HIV-1-infected patients who had been receiving an NVP-containing regimen for at least 2 years were recruited. A total of 613 patients were included with a median follow-up period of 43 months (IQR: 31-51). At baseline, 24.5% (150 patients) were treatment naive, 41.5% (254 patients) switched for simplification purposes, and 34% (209 patients) were failing HAART. Increases by five times or more in AST/ALT values were observed in fewer than 2% of patients. Only 5.7% of all adverse events reported during the investigation were attributable to NVP. The percentage of patients with normal HDL cholesterol levels rose from 17.7% at baseline to 35.4% at the last visit. At the latest time point available for analysis, 76% of naive and 74% of those who had switched had HIV-1 RNA loads of 400 cells/microl (OR: 2.34, 95% CI: 1.22-4.47, p = 0.010). Exposure to nevirapine for up to 4 years is safe. Liver toxicity is infrequent and generally mild. HDL cholesterol levels consistently increase over time and viral suppression is maintained.Keywords
This publication has 22 references indexed in Scilit:
- Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine- or Efavirenz-Based Antiretroviral TherapyClinical Infectious Diseases, 2004
- Lipid Profiles in HIV‐Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles?The Journal of Infectious Diseases, 2004
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- Toxicity of Non-Nucleoside Analogue Reverse Transcriptase InhibitorsSeminars in Liver Disease, 2003
- A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997–1999Clinical Infectious Diseases, 2002
- Alcohol Use and HIV PharmacotherapyAIDS Research and Human Retroviruses, 2002
- Lack of Hepatotoxicity Associated With Nonnucleoside Reverse Transcriptase InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral SuppressionClinical Infectious Diseases, 2002
- Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infectionsHepatology, 2002
- Sex Differences in Nevirapine RashClinical Infectious Diseases, 2001